Sting Agonist C11 is primarily used in immunology and cancer research due to its ability to activate the STING (stimulator of interferon genes) pathway. This activation leads to the production of type I interferons and other cytokines, which play a crucial role in enhancing the immune response against tumors. It is often employed in preclinical studies to evaluate its potential as an immunotherapeutic agent, particularly in the context of cancer immunotherapy. Researchers also utilize it to study the mechanisms of innate immunity and to develop strategies for improving the efficacy of immune-based treatments. Additionally, it may be explored in combination therapies to enhance the anti-tumor effects of other treatments, such as checkpoint inhibitors or vaccines.